Results 251 to 260 of about 106,090 (294)

Angiotensin-converting enzyme inhibitors

2001
Publisher Summary Angiotensin-converting enzyme (ACE) inhibitors were first studied clinically in the 1970s. ACE inhibitors were discovered by taking advantage of previous basic research on the physiology of sodium, potassium, and water homeostasis and blood pressure regulation, in a reciprocal way ACE have also advanced research in this field, and ...
J, Menard, A A, Patchett
openaire   +3 more sources

Angiotensin-Converting Enzyme Inhibitor Angioedema

The Journal of Emergency Medicine, 2012
*Department of Emergency Medicine, University of Michigan/St. Joseph Mercy Emergency Medicine Residency, Ann Arbor, Michigan, and †Department of Emergency Medicine, University of Michigan Health System, Ann Arbor, Michigan Reprint Address:Michaelina R. Bolton, MD, Department of Emergency Medicine, University of Michigan Health System, 1500 E.
Michaelina R, Bolton, Suzanne L, Dooley-Hash   +1 more
openaire   +2 more sources

Angiotensin-converting enzyme inhibitors

Medicine of Ukraine, 2022
The article reflects the issues of pharmacology and pharmacokinetics of the use of drugs belonging to the group of angiotensin – converting enzyme inhibitors. Given the high risks to the life of children and adults, the clinician must have knowledge of the classification, mechanism of action and possible side effects of this group of drugs.
I. M. Yachnyk, N. P. Karpenko, O. V. Kushneryk, N. M. Tarasenko   +3 more
openaire   +1 more source

Angiotensin-Converting Enzyme Inhibitors

Medical Clinics of North America, 1987
In summary, ACE inhibitors are effective in reducing blood pressure as initial therapy in some hypertensive patients and in combination with diuretics and other agents in virtually all hypertensives. ACE inhibitors are uniquely advantageous because of their favorable hemodynamic effects, the lack of adverse metabolic effects, and their ability to ...
openaire   +4 more sources

Angiotensin converting enzyme inhibitors

Pharmaceutisch Weekblad Scientific Edition, 1982
Inhibition of angiotensin converting enzyme (ACE) in patients suffering from renovascular hypertension results in lowering of the blood-pressure. The development of captopril, an orally active ACE inhibitor and the structure-activity relationship of captopril analogues are described.
openaire   +2 more sources

Angiotensin-Converting Enzyme Inhibitors

AACN Advanced Critical Care, 1992
The angiotensin-converting enzyme (ACE) inhibitors available today include Captopril (Capoten), enalapril (Vasotec), enaloprilat (Vasotec IV), lisinopril (Prinivil, Zestril), benazepril (Lotensin), fosinopril (Monopril), and ramipril (Atace). These drugs are used in the treatment of hypertension and congestive heart failure.
openaire   +2 more sources

Oral angiotensin-converting-enzyme inhibitors

American Journal of Health-System Pharmacy, 1997
The pharmacology, pharmacokinetics, clinical uses, adverse effects, drug interactions, dosage, cost, and therapeutic interchange of oral angiotension-converting-enzyme (ACE) inhibitors are reviewed. ACE inhibitors attenuate the formation of angiotension II and may lead to the accumulation of kinins.
openaire   +2 more sources

Angiotensin-Converting Enzyme (ACE) Inhibitors

2015
Angiotensin converting enzyme inhibitors represent a new class of agents which were designed to retain only that unique property. Because of this inhibition, administration of these agents results in the significant reduction of elevated blood pressure of various etiologies and in the amelioration of symptoms associated with congestive heart failure ...
Daniel Thomas Ginat, Jason M. Johnson
openaire   +1 more source

Angiotensin Converting Enzyme (ACE) Inhibitors

Annual Review of Pharmacology and Toxicology, 1982
Angiotensin converting enzyme inhibitors represent a new class of agents which were designed to retain only that unique property. Because of this inhibition, administration of these agents results in the significant reduction of elevated blood pressure of various etiologies and in the amelioration of symptoms associated with congestive heart failure ...
openaire   +2 more sources

Angiotensin-converting enzyme inhibitors

2023
Abstract Few stories in the history of medical research can generate interest and inspire as much as the mythical journey from ‘Poison to Panacea’. When Ferreira travelled from Santiago to London to work in the laboratory of Sir John Vane, he could not have imagined that a bite from Bothrops jararaca, a Brazilian viper, could give rise ...
Roberto Ferrari, Gabriele Guardigli, Biykem Bozkurt   +2 more
openaire   +1 more source